Tetra designs drugs to treat memory loss and cognitive impairment by improving how the brain processes and stores information.

Working with potentially breakthrough technology, our goal is to improve the quality of life in patients suffering from

  • Alzheimer's disease, 
  • other dementias,
  • traumatic brain injury,
  • major psychiatric diseases and
  • neurodevelopmental disorders.

Our Mission


We are a clinical stage company focused on bringing clarity of thought to people suffering from Alzheimer's disease, traumatic brain injury, and schizophrenia.



Tetra's promising drug for Alzheimer's disease is being developed in partnership with the NIH Blueprint Therapeutics program.

Our Scientific Advisory Board offers talent, experience, and a vision for new medicines.

strategic partnerships

superb scientific advisors

The drugs in our pipeline offer a new mechanism focused on PDE4B and PDE4D.​

innovative science

our approach to Pharmaceutical Drug Development